Clinical pharmacology of new histamine H1 receptor antagonists.

@article{Simons1999ClinicalPO,
  title={Clinical pharmacology of new histamine H1 receptor antagonists.},
  author={F. Estelle R. Simons and Keith J. Simons},
  journal={Clinical pharmacokinetics},
  year={1999},
  volume={36 5},
  pages={329-52}
}
The recently introduced H1 receptor antagonists ebastine, fexofenadine and mizolastine, and the relatively new H1 antagonists acrivastine, astemizole, azelastine, cetirizine, levocabastine and loratadine, are diverse in terms of chemical structure and clinical pharmacology, although they have similar efficacy in the treatment of patients with allergic disorders. Acrivastine is characterised by a short terminal elimination half-life (t1/2 beta) [1.7 hours] and an 8-hour duration of action… CONTINUE READING
18 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…